NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Devices · USD

Glaukos Corporation (GKOS) Stock Analysis

Glaukos Corporation (GKOS) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

GKOS

$177.47

−$2.88 (−1.60%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GKOS with… →

GKOS Key Statistics

As of Sep 4, 2026
Trading
Open
$177.80
Previous Close
$180.35
Day's Range
175.14–181.52
52-Week Range
73.16–191.62
Volume
572.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.77
Valuation
Market Cap
$10.47B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
351.89
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
17.08
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.21
Financials (FY)
Revenue (FY)
$507.44M+32.33%
Net Income (FY)
−$187.69M
Profit marginThe share of revenue left as profit after all costs and taxes.
−30.69%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
58.98M
1-Year Return
+96.88%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
820.99K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GKOS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+57.18%
2025−24.70%
2024+88.63%
2023+81.98%
2022−1.71%
2021−40.95%
2020+38.17%
2019−3.03%
2018+118.99%
2017−25.22%
2016 (partial year)+1.99%

As of September 4, 2026.

GKOS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$507.44M−$187.69M−37.0%
2024$383.48M−$146.37M−38.2%
2023$314.71M−$134.66M−42.8%
2022$282.86M−$99.20M−35.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$507.44M$282.76M−$199.60M−$187.69M−37.0%
2024$383.48M$289.45M−$108.14M−$146.37M−38.2%
2023$314.71M$239.14M−$123.70M−$134.66M−42.8%
2022$282.86M$213.88M−$102.31M−$99.20M−35.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GKOS Valuation vs Medical Devices Median

Median of 151 stocks
MetricGKOSMedical Devices medianvs median
P/S ratio17.082.985.7x the median
Profit margin−30.69%−1.69%29.0 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Glaukos Corporation (GKOS) is capitalised at $10.47B on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 1,094 employees.

GKOS last closed at $177.47 on September 4, 2026. That is −$2.88 (−1.60%) against the previous close. Over the past 52 weeks the price has ranged from $73.16 to $191.62. The latest close sits 142.58% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $507.44M. Against the prior fiscal year total of $383.48M, that is a change of +32.33%. The same year closed with a net loss of $187.69M. The reported profit margin is −30.69%. That is 29 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −3.21.

Across the 4 fiscal years on file, revenue moves from $282.86M in 2022 to $507.44M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 351.89. Measured against sales, the shares trade at 17.08 times revenue. On price-to-sales that is 5.7 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 0.77. Annualized volatility over the trailing 10 years is 52.38%. Over the trailing twelve months the price has returned +96.88%. Measured over 10 years, that is +19.18% a year compounded.

Growth & Income

No dividend is on file for GKOS.

2026 is still running; the price is +57.18% year to date. Across the complete calendar years on file, 2018 returned +118.99% and 2021 returned −40.95%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Glaukos Corporation (GKOS) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Glaukos Corporation GKOS $10.47B —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Glaukos Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Glaukos Corporation

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Visit website →